Titanovo Logo
Back to Cell Types

KM-H2Homo sapiens (Human)Cancer cell line

Also known as: KMH2, KM H-2, KHM2/171877 (In old versions.)

🤖 AI SummaryBased on 13 publications

Quick Overview

KM-H2 is a Hodgkin lymphoma cell line with unique genetic features.

Detailed Summary

KM-H2 is a Hodgkin lymphoma cell line derived from a patient with mixed cellularity Hodgkin lymphoma. It exhibits biphenotypic features of dendritic cells and B cells, expressing markers such as CD83, fascin, and DEC-205. The cell line shows high expression of HLA class II molecules and costimulatory molecules like CD40, CD80, and CD86. KM-H2 has been used in studies related to immune evasion mechanisms and tumor microenvironment interactions. It is also noted for its ability to stimulate T cells and its endocytic activity. The cell line has been characterized for its genetic alterations, including mutations in the TNFAIP3 (A20) gene and TP53 gene deletions, which may contribute to its malignant phenotype.

Research Applications

Immune evasion mechanismsTumor microenvironment interactionsGenetic alterations in lymphomaHLA class II expression studies

Key Characteristics

Biphenotypic markers of dendritic cells and B cellsHigh expression of HLA class II moleculesExpression of costimulatory moleculesMutations in TNFAIP3 (A20) geneTP53 gene deletions
Generated on 6/16/2025

Basic Information

Database IDCVCL_1330
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age37
Age CategoryAdult
SexMale

Disease Information

DiseaseHodgkin lymphoma
LineageLymphoid
SubtypeHodgkin Lymphoma
OncoTree CodeHL

DepMap Information

Source TypeDSMZ
Source IDACH-000815_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationUnexplicitTNFAIP3In2-Ex6 delHeterozygous-PubMed=19380639
Gene deletionTNFAIP3-Heterozygous-PubMed=19380639
Gene fusionMGMTPRRC2B-MGMT, BAT2L1-MGMT--PubMed=21368758
Gene fusionCIITACIITA-C15orf65, CIITA-PIERCE2--PubMed=21368758

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,14
D13S317
10,11
D16S539
9
D18S51
15
D19S433
14,16
D21S11
30,31.2,32.2
D2S1338
20,24
D3S1358
15,16
D5S818
11,13
D7S820
10,11,12
D8S1179
10
FGA
23,24
Penta D
10,11
Penta E
15,18
TH01
7,9
TPOX
8,10,11,12
vWA
17,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";

Drexler H.G., Pommerenke C., Eberth S., Nagel S.

Biol. Chem. 399:511-523(2018).

DOIPubMed

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A mass spectrometric-derived cell surface protein atlas.";

Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

PLoS ONE 10:E0121314-E0121314(2015).

DOIPubMedPMC

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

J. Virol. 89:713-729(2015).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.

Gascoyne R.D.

Nature 471:377-381(2011).

DOIPubMedPMC

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Kutok J.L., Shipp M.A.

Blood 116:3268-3277(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

Stanelle J., Siebert R., Kuppers R.

J. Exp. Med. 206:981-989(2009).

DOIPubMedPMC

A novel HLA-DRB1 allele, HLA-DRB1*0465, was identified in a Hodgkin's lymphoma cell line.

Witter K., Mautner J., Volgger A., Zahn R., Kauke T.

Tissue Antigens 71:257-258(2008).

DOIPubMed

Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma.

Sturzenhofecker B., Kube D.

Leuk. Lymphoma 47:1932-1940(2006).

DOIPubMed

A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of dendritic cells and B cells.

Fujimoto M., Inaba M., Fukuhara S.

Int. J. Hematol. 73:236-244(2001).

DOIPubMed

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Quentmeier H., Drexler H.G.

Leukemia 10:142-149(1996).

PubMed

Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.

Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.

Br. J. Haematol. 91:350-354(1995).

DOIPubMed

Reed-Sternberg cells in Hodgkin's cell lines HDLM, L-428, and KM-H2 are not actively replicating: lack of bromodeoxyuridine uptake by multinuclear cells in culture.

Lok M.-S., Fukuhara S.

Blood 71:1382-1389(1988).

DOIPubMed

Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease.

Shirakawa S., Hatanaka M., Honjo T.

Blood 68:285-292(1986).

DOIPubMed

Biology of Hodgkin cell lines.";

Tesch H., Fonatsch C., Stein H., Diehl V.

Recent Results Cancer Res. 117:53-61(1989).

DOIPubMed

A new hypothesis on the cellular origin of Reed-Sternberg and Hodgkin cells based on the immunological and molecular genetic analysis of the KM-H2 line.

Kamesaki H., Fukuhara S., Uchino H., Nosaka T.

Recent Results Cancer Res. 117:83-90(1989).

DOIPubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

tcpaportal.org